Summary
Depression is a heterogeneous disease state characterised by complex alterations in several CNS neurotransmitter and receptor systems. All antidepressants are thought to act by causing postsynaptic adaptive changes (e.g. in transducers or second messengers) within these systems. Thus, the mechanism of action of selective serotonin reuptake inhibitors (SSRIs) cannot simply be explained in terms of inhibition of serotonin (5-hydroxytryptamine) [5-HT] reuptake. Fluvoxamine, sertraline and fluoxetine downregulate central β-adrenoceptors, and all SSRIs are believed to normalise central 5-HT1A- and 5-HT2-receptor density and function in patients with depression.
SSRIs are as effective as tricyclic antidepressants in the treatment of depression, but have distinct tolerability advantages — they are not associated with anticholinergic adverse effects, cardiotoxicity, sedation or weight gain. However, gastrointestinal reactions (e.g. nausea, diarrhoea/loose stools, constipation) are relatively common during SSRI therapy. Additionally, in contrast to tricyclic antidepressants, SSRI dosage adjustments appear to be unnecessary in elderly depressed patients. Fluvoxamine has a much shorter elimination half-life than fluoxetine and its active metabolite, norfluoxetine, and therefore a reduced potential for drug interactions. Only small amounts of fluvoxamine and fluoxetine, but large quantities of paroxetine, are secreted in breast milk. Furthermore, genetic polymorphism has not been documented for fluvoxamine metabolism, whereas slow and fast metabolisers of paroxetine, and fast metabolisers of fluoxetine have been identified.
SSRIs have a better tolerability profile than tricyclic antidepressants, as indicated by lower mean rank scores for behavioural toxicity. Moreover, SSRIs are associated with a much lower incidence of fatal toxicity than tricyclics, and appear to be relatively safe in overdosage.
Thus, SSRIs represent a class of antidepressants with similar efficacy to, but major tolerability advantages over, tricyclic agents. Continued use of and experience with SSRIs will enhance our understanding of the central serotonergic system and may lead to the development of more selective drugs in the future.
Similar content being viewed by others
References
Åberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. British Journal of Psychiatry 155 (Suppl. 8): 32–40, 1989
Bech P. A meta-analysis of the antidepressant properties of serotonin reuptake inhibitors. International Review of Psychiatry 2: 209–211, 1990
Bergstrom RF, Lemberger L, Farid NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine. A review. British Journal of Psychiatry 153 (Suppl. 3): 47–50, 1988
Butler J, Leonard BE. Clinical and experimental studies on fluoxetine: effects on serotonin uptake. International Clinical Psychopharmacology 5: 41–48, 1990
Byerley WF, McConnell EJ, McCabe RT, Dawson TM, Grosser BI, et al. Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology 94: 141–143, 1988
Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. Journal of Clinical Psychopharmacology 10: 48–50, 1990
Coppen AJ, Doogan BP. Serotonin and its place in the pathogenesis of depression. Journal of Clinical Psychiatry 49 (Suppl.): 4–11, 1988
Cowen PJ. Antidepressants: current concepts of mode of action. International Clinical Psychopharmacology 5 (Suppl. 3): 45–55, 1990
Cowen PJ. Serotonin receptor subtypes: implications for psychopharmacology. British Journal of Psychiatry 159 (Suppl. 12): 7–14, 1991
Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 225–253, 1991
Doogan DP, Gaillard V. Sertraline: a new antidepressant. Journal of Clinical Psychiatry 49 (Suppl.): 46–51, 1988
Gonzalez-Heydrich J, Peroutka SJ. Serotonin receptor and reuptake sites: pharmacologic significance. Journal of Clinical Psychiatry 51 (Suppl. 4): 5–12, 1990
Gram LF. Plasma concentrations of antidepressants and clinical response: state-of-the-art. Proceedings of 5th World Congress of Biological Psychiatry, Florence, June 9–14, 1991. In Racagni G (Ed.) Biological psychiatry, Vol. 1, pp. 359–361, Elsevier, Amsterdam, 1991
Isenberg KE. Excretion of fluoxetine in human breast milk. Journal of Clinical Psychiatry 51: 169, 1990
Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica 80 (Suppl. 350): 60–75, 1989
Kerr IS, Sherwood N, Hindmarch I. The comparative psycho-pharmacology of 5HT reuptake inhibitors. Human Psycho-pharmacology 6: 313–318, 1991
Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor or serotonin reuptake. Journal of Clinical Psychiatry 51 (Suppl. B): 13–17, 1990
Koe BK, Koch SW, Lebel SA, Minor KW, Page MG. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of -adrenoceptor system of rat brain. European Journal of Pharmacology 141: 187–194, 1987
Koe BK, Vinick FJ. Adaptive changes in central nervous system receptor systems. Annual Reports in Medicinal Chemistry 19: 41–49, 1984
Leonard BE. Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review. Human Psychopharmacology 1: 3–21, 1986
Leonard BE. Lofepramine: pharmacology and mode of action. International Clinical Psychopharmacology 3: 25–38, 1988
Leonard BE. Pharmacological and biochemical aspects of therapyresistant depression. International Clinical Psychopharmacology 6 (Suppl. 1): 13–29, 1990a
Leonard BE. Changes in platelet serotonergic and adrenergic function in patients with depression, panic attack and mania. In Bunney et al. (Eds) Neuropsychopharmacology, pp. 162–171, Springer Verlag, Berlin, 1990b
Mück-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. Journal of Affective Disorders 23: 157–164, 1991
Price LH. Serotonin reuptake inhibitors in depression and anxiety. An overview. Annals of Clinical Psychiatry 2: 165–172, 1990
Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, et al. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Journal of Clinical Psychiatry 5 (Suppl. 4): 44–50, 1990
Racagni G, Tinelli D, Bianchi E, Brunello N, Perez J. cAMP-dependent binding proteins and endogenous phosphorylation after antidepressant treatment. In Sandier M, et al. (Eds) 5-Hydroxytryptamine in psychiatry, pp. 116–123, Oxford University Press, Oxford, 1991
Raghoebar M, Roseboom H. Kinetics of fluvoxamine in special populations. Poster presented at the Symposium on Variability in Pharmacokinetics and Drug Response, Gothenburg, October 3–5, 1988
van Harten J. Comparative pharmacokinetics of selective serotonin reuptake inhibitors. A review. Clinical Pharmacokinetics, in press, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leonard, B.E. Pharmacological Differences of Serotonin Reuptake Inhibitors and Possible Clinical Relevance. Drugs 43 (Suppl 2), 3–10 (1992). https://doi.org/10.2165/00003495-199200432-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200432-00003